2021 KUMC Virtual Multidisciplinary Oncology Review
mCRC Updates: FOLFOXIRI+Bev for Unresectable Disease, CEND-1+Neoadjuvant FOLFIRINOX, CRS-HIPEC for Colorectal Peritoneal Carcinomatosis, Oligometastatic Disease
Login to view comments.
Click here to Login